P Mathew

Summary

Affiliation: University of New Mexico
Country: USA

Publications

  1. pmc Current difficulties and recent advances in bypass therapy for the management of hemophilia with inhibitors: a new and practical formulation of recombinant factor VIIa
    Linda Butros
    The University of New Mexico, Albuquerque, New Mexico 87131, USA
    Drug Des Devel Ther 5:275-82. 2011
  2. ncbi request reprint Isotopic synovectomy with P-32 in paediatric patients with haemophilia
    P Mathew
    Department of Pediatrics, Medical College of Ohio Hospital, Toledo, Ohio, USA
    Haemophilia 6:547-55. 2000
  3. doi request reprint A phase II study of amifostine in children with myelodysplastic syndrome: a report from the Children's Oncology Group study (AAML0121)
    Prasad Mathew
    Department of Pediatrics, University of New Mexico, Albuquerque, New Mexico 87131 0001, USA
    Pediatr Blood Cancer 57:1230-2. 2011
  4. ncbi request reprint Recombinant factor VIIa in paediatric bleeding disorders--a 2006 review
    P Mathew
    Department of Pediatrics, University of New Mexico, Albuquerque, NM 87131 0001, and Children s Hospital of Orange County, Orange, CA, USA
    Haemophilia 12:457-72. 2006
  5. ncbi request reprint Current opinion on inhibitor treatment options
    Prasad Mathew
    Department of Pediatrics, University of New Mexico, Albuquerque, NM 87113, USA
    Semin Hematol 43:S8-13. 2006
  6. ncbi request reprint Therapeutic choices in the current millennium: hemophilia workshop highlights
    Prasad Mathew
    Department of Pediatrics, University of New Mexico, Albuquerque, NM 87131, USA
    Pediatr Blood Cancer 45:611-5. 2005
  7. ncbi request reprint The use of rFVIIa in non-haemophilia bleeding conditions in paediatrics. A systematic review
    Prasad Mathew
    University of New Mexico, Department of Pediatrics, MSC 10 5590, 1 University of New Mexico, Albuquerque, New Mexico, 87131 0001, USA
    Thromb Haemost 92:738-46. 2004
  8. ncbi request reprint Conclusion
    Prasad Mathew
    Ted R Montoya Hemophilia Treatment Center, University of New Mexico School of Medicine, Albuquerque, New Mexico, USA
    Blood Coagul Fibrinolysis 15:S19. 2004
  9. ncbi request reprint Recombinant versus plasma-derived factor IX in the treatment of hemophilia B: proceedings of a meeting held in June 2003
    Prasad Mathew
    Ted R Montoya Hemophilia Treatment Center, University of New Mexico School of Medicine, Albuquerque, USA
    Blood Coagul Fibrinolysis 15:S1-3. 2004
  10. ncbi request reprint Is there a potential role for serum cardiac troponin I as a marker for myocardial dysfunction in pediatric patients receiving anthracycline-based therapy? A pilot study
    P Mathew
    Division of Hematology Oncology, Department of Pediatrics, University of New Mexico, ACC 3rd Floor, 2211 Lomas Blvd, NE, Albuquerque, NM 87131 5311, USA
    Cancer Invest 19:352-9. 2001

Collaborators

Detail Information

Publications24

  1. pmc Current difficulties and recent advances in bypass therapy for the management of hemophilia with inhibitors: a new and practical formulation of recombinant factor VIIa
    Linda Butros
    The University of New Mexico, Albuquerque, New Mexico 87131, USA
    Drug Des Devel Ther 5:275-82. 2011
    ....
  2. ncbi request reprint Isotopic synovectomy with P-32 in paediatric patients with haemophilia
    P Mathew
    Department of Pediatrics, Medical College of Ohio Hospital, Toledo, Ohio, USA
    Haemophilia 6:547-55. 2000
    ..As previously shown, MRI appears to give more detailed information about joint arthropathy than plain radiographs...
  3. doi request reprint A phase II study of amifostine in children with myelodysplastic syndrome: a report from the Children's Oncology Group study (AAML0121)
    Prasad Mathew
    Department of Pediatrics, University of New Mexico, Albuquerque, New Mexico 87131 0001, USA
    Pediatr Blood Cancer 57:1230-2. 2011
    ..The role of amifostine in pediatric MDS was not known at the time of study...
  4. ncbi request reprint Recombinant factor VIIa in paediatric bleeding disorders--a 2006 review
    P Mathew
    Department of Pediatrics, University of New Mexico, Albuquerque, NM 87131 0001, and Children s Hospital of Orange County, Orange, CA, USA
    Haemophilia 12:457-72. 2006
    ..rFVIIa has been administered as both bolus and continuous infusions, and at varying doses. Furthermore, adverse events have not reportedly increased in children despite growing experience with its use in the paediatric population...
  5. ncbi request reprint Current opinion on inhibitor treatment options
    Prasad Mathew
    Department of Pediatrics, University of New Mexico, Albuquerque, NM 87113, USA
    Semin Hematol 43:S8-13. 2006
    ..Both the cost of therapy and the outcome of therapy will need to be considered in the development of future hemostatic agents for patients with inhibitors...
  6. ncbi request reprint Therapeutic choices in the current millennium: hemophilia workshop highlights
    Prasad Mathew
    Department of Pediatrics, University of New Mexico, Albuquerque, NM 87131, USA
    Pediatr Blood Cancer 45:611-5. 2005
    ..This paper provides a summary of the discussions at these workshops. Despite the progress made in the management of patients with hemophilia, the workshop highlighted the fact that there were still many unanswered questions...
  7. ncbi request reprint The use of rFVIIa in non-haemophilia bleeding conditions in paediatrics. A systematic review
    Prasad Mathew
    University of New Mexico, Department of Pediatrics, MSC 10 5590, 1 University of New Mexico, Albuquerque, New Mexico, 87131 0001, USA
    Thromb Haemost 92:738-46. 2004
    ..However, most of the published work is mainly anecdotal, case reports or small series. Randomized trials in children are eagerly awaited...
  8. ncbi request reprint Conclusion
    Prasad Mathew
    Ted R Montoya Hemophilia Treatment Center, University of New Mexico School of Medicine, Albuquerque, New Mexico, USA
    Blood Coagul Fibrinolysis 15:S19. 2004
  9. ncbi request reprint Recombinant versus plasma-derived factor IX in the treatment of hemophilia B: proceedings of a meeting held in June 2003
    Prasad Mathew
    Ted R Montoya Hemophilia Treatment Center, University of New Mexico School of Medicine, Albuquerque, USA
    Blood Coagul Fibrinolysis 15:S1-3. 2004
  10. ncbi request reprint Is there a potential role for serum cardiac troponin I as a marker for myocardial dysfunction in pediatric patients receiving anthracycline-based therapy? A pilot study
    P Mathew
    Division of Hematology Oncology, Department of Pediatrics, University of New Mexico, ACC 3rd Floor, 2211 Lomas Blvd, NE, Albuquerque, NM 87131 5311, USA
    Cancer Invest 19:352-9. 2001
    ..In addition, larger sample size or longer follow-up may be helpful to determine if higher doses or symptomatic patients potentially have elevations in cTnI levels...
  11. ncbi request reprint Novel applications of recombinant factor VIIa for the management of pediatric coagulopathic diseases
    Prasad Mathew
    University of New Mexico, Department of Pediatrics, Pediatric Hematology Oncology, Albuquerque, New Mexico 87131 5311, USA
    J Pediatr Hematol Oncol 25:499-502. 2003
    ..Using laboratory and clinical measures of outcome, the use of rVIIa as a therapeutic option in treating several different pediatric coagulopathic conditions is described...
  12. ncbi request reprint Efficacy of colony-stimulating factors in acute leukemia
    M T Holdsworth
    College of Pharmacy and Department of Pediatrics, University of New Mexico, Albuquerque, NM 87131 5691, USA
    Ann Pharmacother 35:92-108. 2001
    ..To evaluate the literature describing the safety and efficacy of the hematopoietic colony-stimulating factors (CSFs) for the management of treatment-related adverse effects in patients with acute leukemia...
  13. ncbi request reprint Pain and distress from bone marrow aspirations and lumbar punctures
    Mark T Holdsworth
    Pharmacy and Pediatrics, College of Pharmacy, University of New Mexico, Albuquerque, NM 87131 1066, USA
    Ann Pharmacother 37:17-22. 2003
    ..To compare the efficacy of 3 different pharmacologic regimens to relieve pain and distress in children with cancer undergoing bone marrow aspirations (BMAs) and lumbar punctures (LPs)...
  14. ncbi request reprint How we manage requests for recombinant factor VIIa (NovoSeven)
    Prasad Mathew
    Department of Pathology, University of New Mexico, New Mexico, USA
    Transfusion 47:8-14. 2007
  15. doi request reprint PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers
    I A Ivens
    Bayer HealthCare Pharmaceuticals, San Francisco, CA, USA
    Haemophilia 19:11-20. 2013
    ..Chronic use of currently available PEGylated products has been shown to be safe, paving the way for chronic use of PEGylated coagulation products in persons with haemophilia...
  16. doi request reprint Thrombotic events in neonates receiving recombinant factor VIIa or fresh frozen plasma
    John Puetz
    Division of Hematology Oncology, Department of Pediatrics, Saint Louis University, SSM Cardinal Glennon Children s Medical Center, St Louis, Missouri 63104, USA
    Pediatr Blood Cancer 53:1074-8. 2009
    ..The prevalence of thrombotic events in these neonates is completely unknown. This study was initiated to determine the risk of thrombotic events associated with rFVIIa use in neonates...
  17. doi request reprint The laboratory approach to inherited and acquired coagulation factor deficiencies
    Benjamin L Wagenman
    Department of Pathology, University of New Mexico, TriCore Reference Laboratories, 915 Camino de Salud NE, Albuquerque, NM 87102, USA
    Clin Lab Med 29:229-52. 2009
    ..Understanding the optimal laboratory approach to evaluating factor deficiency will aid physicians and laboratory scientists in obtaining a prompt diagnosis and in avoiding pitfalls in coagulation testing...
  18. ncbi request reprint Recombinant factor VIIa in management of spontaneous subcapsular liver hematoma associated with pregnancy
    Shakil H Merchant
    Department of Pathology, University of New Mexico, Albuquerque, New Mexico 87131, USA
    Obstet Gynecol 103:1055-8. 2004
    ..Spontaneous subcapsular liver hemorrhage is a rare but life-threatening complication of pregnancy. Optimal management of an expanding hematoma or ruptured capsule has not been established...
  19. ncbi request reprint Recombinant activated factor VII as an adjunct to packing for liver injury with hepatic venous disruption
    Joachim Chino
    Department of Surgery, University of New Mexico Health Sciences Center, Albuquerque, NM 87131 0001, USA
    Am Surg 71:595-7. 2005
    ..We report two children with hepatic venous injury requiring perihepatic packing and recombinant activated factor VII to successfully control hemorrhage...
  20. doi request reprint Alpha2-antiplasmin and its deficiency: fibrinolysis out of balance
    S L Carpenter
    Department of Pediatrics, University of Texas Health Science Center, San Antonio, TX 78207, USA
    Haemophilia 14:1250-4. 2008
    ..We also discuss some of the current avenues of investigation into its impact on other diseases and physiological states...
  21. ncbi request reprint Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors
    Ashish V Joshi
    Novo Nordisk Inc, Princeton, NJ, USA
    Curr Med Res Opin 22:23-31. 2006
    ....
  22. ncbi request reprint Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery. Results from an open-label, randomized, multicenter trial
    Rajiv K Pruthi
    Comprehensive Hemophilia Center, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Thromb Haemost 98:726-32. 2007
    ..Serious adverse events were related to continued or increased bleeding. In conclusion, haemostatic efficacy and safety of BI and CI of rFVIIa are comparable for the surgical management of haemophilia subjects with inhibitors...
  23. ncbi request reprint Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia
    Marilyn J Manco-Johnson
    University of Colorado and Health Sciences Center, Denver, USA
    N Engl J Med 357:535-44. 2007
    ..Effective ways to prevent arthropathy in severe hemophilia are unknown...
  24. ncbi request reprint Chronic hepatitis B and other correlates of spontaneous clearance of hepatitis C virus among HIV-infected people with hemophilia
    Lehida Melendez-Morales
    Viral Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, 6120 Executive Boulevard, Rockville, MD 20852, USA
    AIDS 21:1631-6. 2007
    ..To identify correlates of spontaneous hepatitis C virus (HCV) clearance among people with human immunodeficiency virus (HIV) co-infection...